Science
Science
Qymune's Q²TCE platform introduces a first-in-class, unconventional approach to T cell engagement that delivers potent cytotoxicity with markedly reduced cytokine release. Tunable antibody affinities enable application across oncology and autoimmune diseases, expanding patient eligibility and combination potential beyond conventional T cell engagers.
Qymune's Q²TCE platform introduces a first-in-class, unconventional approach to T cell engagement that delivers potent cytotoxicity with markedly reduced cytokine release. Tunable antibody affinities enable application across oncology and autoimmune diseases, expanding patient eligibility and combination potential beyond conventional T cell engagers.
How Q²TCE works differently
How Q²TCE works differently
How Q²TCE works differently
T cell engagers are incredibly potent at killing cancer cells, but current CD3-based approaches cause severe cytokine release syndrome. For autoimmune diseases requiring chronic treatment, this toxicity profile is a dealbreaker.
T cell engagers are incredibly potent at killing cancer cells, but current CD3-based approaches cause severe cytokine release syndrome. For autoimmune diseases requiring chronic treatment, this toxicity profile is a dealbreaker.
Conventional Approach
vs
Q²TCE
Cancer cell
T cell
Excessive cytokine
Zero or near Zero
cytokine release
Potency
Achieves deeper tissue depletion than standard antibodies, eliminating hidden reservoirs.
Accessibility
Ready-to-use / Off-the-shelf. Solves the manufacturing delays and high costs of CAR-T.
Platform
A versatile, first-in-class engine designed for broad scalability across diverse therapeutic targets.
Safety
Redefining the therapeutic window- maximal efficacy without the systemic risks
Conventional Approach
vs
Q²TCE
Cancer cell
T cell
Zero or near Zero
cytokine release
Potency
Achieves deeper tissue depletion than standard antibodies, eliminating hidden reservoirs.
Accessibility
Ready-to-use / Off-the-shelf. Solves the manufacturing delays and high costs of CAR-T.
Platform
A versatile, first-in-class engine designed for broad scalability across diverse therapeutic targets.
Safety
Redefining the therapeutic window- maximal efficacy without the systemic risks
Conventional Approach
vs
Q²TCE
Cancer cell
T cell
Zero or near Zero
cytokine release
Potency
Accessibility
Platform
Safety
OUR PLATFORM
Qymune is building the next-generation T cell engager (TCE) platform to overcome the fundamental limitations of current approaches
Qymune is building the next-generation T cell engager (TCE) platform to overcome the fundamental limitations of current approaches
Qymune is building the next-generation T cell engager (TCE) platform to overcome the fundamental limitations of current approaches
Our platforms are engineered to deliver durable efficacy, precise immune control, and best-in-class safety, enabling applications across oncology and immune-mediated diseases.
Our platforms are engineered to deliver durable efficacy, precise immune control, and best-in-class safety, enabling applications across oncology and immune-mediated diseases.
Q²TCE — Quiet T Cell Engager Platform
Safety by Design
Q²TCE — Quiet T Cell Engager Platform
Safety by Design
T Cell Boosting Technology
Enabling Druable Therapeutic Effect
T Cell Boosting Technology
Enabling Druable Therapeutic Effect
Antibody-Masking Technology
Precision Targeting Through Controlled Activation
Antibody-Masking Technology
Precision Targeting Through Controlled Activation
Together, these platforms form the foundation of Qymune’s next-generation T cell engager strategy—designed to deliver powerful, durable efficacy with uncompromising patient safety.
Together, these platforms form the foundation of Qymune’s next-generation T cell engager strategy—designed to deliver powerful, durable efficacy with uncompromising patient safety.
